Abstract:Evaluation of the metabolome could discover novel biomarkers of disease. To date, characterization of the serum metabolome of client-owned cats with chronic kidney disease (CKD), which shares numerous pathophysiological similarities to human CKD, has not been reported. CKD is a leading cause of feline morbidity and mortality, which can be lessened with early detection and appropriate treatment. Consequently, there is an urgent need for early-CKD biomarkers. The goal of this cross-sectional, prospective study was to characterize the global, non-targeted serum metabolome of cats with early versus late-stage CKD compared to healthy cats. Analysis revealed distinct separation of the serum metabolome between healthy cats, early-stage and late-stage CKD. Differentially abundant lipid and amino acid metabolites were the primary contributors to these differences and included metabolites central to the metabolism of fatty acids, essential amino acids and uremic toxins. Correlation of multiple lipid and amino acid metabolites with clinical metadata important to CKD monitoring and patient treatment (e.g. creatinine, muscle condition score) further illustrates the relevance of exploring these metabolite classes further for their capacity to serve as biomarkers of early CKD detection in both feline and human populations.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify the differences in the serum metabolome between pet cats with early - and late - stage chronic kidney disease (CKD) and healthy cats through non - targeted metabolomics analysis, in order to discover potential early - stage CKD biomarkers. Specifically, the study aims to: 1. **Describe the serum metabolome characteristics of cats at different stages of CKD**: By comparing the serum metabolomes of healthy cats, early - stage CKD cats, and late - stage CKD cats, reveal the metabolic changes at different disease stages. 2. **Identify specific metabolites in early - and late - stage CKD**: Determine which metabolites show significant differences in early - and late - stage CKD, especially lipid and amino acid metabolites. 3. **Explore the potential of these metabolites as early - stage CKD biomarkers**: Evaluate whether these differential metabolites can be used as potential biomarkers for early - stage CKD detection, thereby providing a basis for early diagnosis and treatment. ### Research Background Chronic kidney disease (CKD) is a common disease in cats, which can lead to significant physiological and metabolic disorders, including problems such as muscle atrophy, malnutrition, amino acid metabolism disorders, and oxidative stress. The International Renal Interest Society (IRIS) recommends using alternative indicators such as creatinine and symmetric dimethylarginine (SDMA) to stage the disease according to the severity of the disease (stages 1 - 4). However, the symptoms of early - stage CKD are often not obvious, resulting in difficulty in timely diagnosis. Therefore, finding biomarkers that can identify CKD at an early stage is crucial for improving prognosis. ### Methods The researchers used a non - targeted metabolomics method to analyze the serum samples of 56 cats (25 healthy cats, 30 CKD cats, of which 17 were early - stage CKD and 13 were late - stage CKD). Through partial least squares discriminant analysis (PLS - DA) and hierarchical clustering analysis (HCA), the key metabolites that distinguish healthy cats, early - stage CKD cats, and late - stage CKD cats were identified. ### Main Findings 1. **Significant separation of the metabolome**: There are significant differences in the serum metabolomes of healthy cats, early - stage CKD cats, and late - stage CKD cats, especially in lipid and amino acid metabolites. 2. **Changes in lipid metabolism**: Lipid metabolism is the main driving factor for distinguishing different disease stages, especially the changes in fatty acid, phospholipid, and glyceride metabolic pathways. 3. **Changes in amino acid metabolism**: In CKD cats, especially in late - stage CKD cats, multiple essential amino acids (such as arginine, histidine, phenylalanine, threonine, and tryptophan) are significantly reduced. 4. **Changes in uremic toxin metabolism**: In CKD cats, certain uremic toxin precursors (such as tryptophan, tyrosine, and phenylalanine) are significantly reduced, while certain uremic toxins (such as methylindole - 3 - acetic acid) are increased. ### Conclusion This study shows that through non - targeted metabolomics analysis, specific metabolic changes in early - and late - stage CKD cats can be identified, especially the changes in lipid and amino acid metabolites. These findings provide new insights for further understanding the pathophysiological mechanisms of CKD and may provide valuable clues for the development of diagnostic tools and treatment strategies for early - stage CKD.

Untargeted metabolomic profiling of serum from client-owned cats with early and late-stage chronic kidney disease

In-depth characterisation of the urine metabolome in cats with and without urinary tract diseases

Untargeted Metabolomics by Ultra-High-Performance Liquid Chromatography Coupled with Electrospray Ionization-Quadrupole-Time of Flight-Mass Spectrometry Analysis Identifies a Specific Metabolomic Profile in Patients with Early Chronic Kidney Disease

Unbiased serum metabolomic analysis in cats with naturally occurring chronic enteropathies before and after medical intervention

Renal biomarkers in cats: A review of the current status in chronic kidney disease

Metabolic Assessment in Non-Dialysis Patients with Chronic Kidney Disease

Urinary D-amino acid profiles in cats with chronic kidney disease

Diagnosis of the cat with early chronic kidney disease

Identification of serum biomarkers for chronic kidney disease using serum metabolomics

Analysis of serum proteomic in cats with polycystic kidney disease-1 gene mutation

A Metabolomics study of metabolites associated with the glomerular filtration rate

Relationship between FGF 23, SDMA, Urea, Creatinine and Phosphate in Relation to Feline Chronic Kidney Disease

Clinical evaluation of dietary modification for treatment of spontaneous chronic kidney disease in cats

Preliminary evaluation of fecal fatty acid concentrations in cats with chronic kidney disease and correlation with indoxyl sulfate and p‐cresol sulfate

NMR-Based Metabolomics in Differential Diagnosis of Chronic Kidney Disease (CKD) Subtypes

8-Hydroxy-2'-deoxyguanosine and malondialdehyde in plasma and their association with disease severity in 20 cats with chronic kidney disease

Untargeted and spatial-resolved metabolomics characterize serum and tissue-specific metabolic reprogramming in acute kidney injury

Integration of Urinary Peptidome and Fecal Microbiome to Explore Patient Clustering in Chronic Kidney Disease

Evaluation of Serum Symmetric Dimethylarginine Concentration as a Marker for Masked Chronic Kidney Disease in Cats With Hyperthyroidism

Deliverables from Metabolomics in Kidney Disease: Adenine, New Insights, and Implication for Clinical Decision-Making

Clinical and Nutritional Follow-up of Cats with Chronic Kidney Disease Fed with a Renal Prescription Diet